Dot1L-IN-2;2,4-Pyrimidinediamine, N4-methyl-N2-[2-methyl-1-[2-[(3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)oxy]phenyl]-1H-indol-6-yl]-;Dot1L IN 2,Dot1LIN2,Dot-1L-IN-2
Dot1L-IN-2 is used as a potent, selective, and orally available inhibitor of Dot1L (a histone methyltransferase); it inhibits H3K79 dimethylation, suppresses the activity of the HoxA9 promoter, and dramatically inhibits the proliferation of human MLL-rearranged leukemia cells (e.g., MV4-11 cells harboring the oncogenic MLL-AF4 fusion).